From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.

Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.

Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.

While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities.